Walleye Capital LLC Invests $1.39 Million in Genmab A/S Sponsored ADR $GMAB

Key Points

• Walleye Capital LLC acquired a new position in Genmab A/S, purchasing 70,862 shares valued at approximately $1.39 million in the first quarter.
• Genmab A/S stock opened at $24.87, down 1.0%, with a market capitalization of $15.96 billion and a 52-week range between $17.24 and $27.93.
• The company reported earnings of $0.54 per share for the last quarter, surpassing estimates, while its revenue was significantly lower than expected at $925 million.

Walleye Capital LLC bought a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 70,862 shares of the company's stock, valued at approximately $1,387,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Deep Track Capital LP acquired a new stake in Genmab A/S in the 4th quarter valued at approximately $41,740,000. Brandywine Global Investment Management LLC grew its holdings in shares of Genmab A/S by 6.0% during the 1st quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock worth $33,627,000 after purchasing an additional 97,633 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after purchasing an additional 938,455 shares in the last quarter. Two Sigma Advisers LP grew its holdings in shares of Genmab A/S by 168.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. Finally, Voloridge Investment Management LLC grew its holdings in shares of Genmab A/S by 102.4% during the 4th quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company's stock worth $23,170,000 after purchasing an additional 561,767 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Analyst Ratings Changes

GMAB has been the topic of several recent research reports. HC Wainwright lifted their price objective on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, August 15th. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Truist Financial lifted their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Finally, Zacks Research lowered Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.60.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded up $1.04 during midday trading on Wednesday, hitting $26.93. 1,700,496 shares of the company were exchanged, compared to its average volume of 1,441,633. The firm has a market cap of $17.27 billion, a P/E ratio of 13.50, a PEG ratio of 7.22 and a beta of 0.93. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $27.91. The firm has a 50 day simple moving average of $22.41 and a 200-day simple moving average of $21.34.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.